Treatment of cardiac diseases: Evidence based or experience based medicine?

Heart

Volumn 84, Issue 2, 2000, Pages 134-136

  Kubler W ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANGINA PECTORIS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; EVIDENCE BASED MEDICINE; HEART DISEASE; HEART INFARCTION; HUMAN; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 1642633478     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.84.2.134     Document Type: Review

References (19)

1. Echt DS, Liebson PR, Mitchell B, et al, and the CAST investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
2. Committee of Principal Investigators. Report on a WHO cooperative trial on primary prevention of ischemic heart disease using clofibrate to lower serum cholesterol. Lancet 1980;ii:379-85.
3. LeLorier J, Gregoir G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomised, controlled trials. N Engl J Med 1997;337:536-42.
4. Maseri A. Evidence-based medicine: progress but not a final solution. Clin Cardiol 1998;21:463-4.
5. Parisi AF, Folland ED, Hartigan P, on behalf of the veterans affairs ACME investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992;326:10-16.
6. RITA-2 trial participants. Coronary angioplasty versus medical therapy for angina: the second randomized intervention treatment of angina (RITA-2) trial. Lancet 1997;350:461-8.
7. Passamani E, Davies KB, Gillespie MJ, et al, and the CASS principal investigators and associates. A randomized trial of coronary artery bypass surgery: survival of patients with a low ejection fraction. N Engl J Med 1985;312:1665-71.
8. Goldberg RJ, Yarzebski J, Lessard D, et al. A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol 1999;33:1533-9.
9. Abel U. "Statistisch signifikant" - eine Überschätzung des Erkenntniswerts? Med Klin 1999;94(suppl II):21-2.
10. Guttenberger R. Klinische Studien - Was ist die Fragestellung? Med Klin 1999;94(suppl II):14-16.
11. Laaser U. Das Gesundheitswesen in Deutschland: Von der Ausgaben - zur Ergebnisorientierung. In: Laaser U, Schwalbe A, eds. Schriftenreihe Gesundheit - Pflege - Soziale Arbeit, vol 1. Lage, Germany: Verlag Hans Jacobs, 1999:9-17.
12. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
13. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TeXCAPS. JAMA 1998;279:1615-22.
14. Kübler W, Kreuzer J. Primäre und sekundäre Prävention der koronaren Herzerkrankung: Was können wir uns leisten? Z Kardiol 1999;88:85-9.
15. Conti CR. Clinical trials and the cost of medical care. Clin Cardiol 1999;22:549-50.
16. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
17. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/ IIIa integrin in ischemic heart disease. Circulation 1998;98: 2829-35.
18. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
19. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336: 1689-96.